Regencell bioscience holdings limited establishes a joint venture to offer covid treatment

Hong kong--(business wire)--regencell bioscience holdings limited (nasdaq: rgc) (“regencell” or the “company”), today announced that regencell bioscience limited (“regencell hk”), the company's wholly-owned subsidiary in hong kong, has entered into a joint venture agreement with honor epic enterprises limited (“honor epic”). the joint venture (“jv”) is expected to offer covid-19 (“covid”) related treatments to patients in asean countries, india, japan, australia and new zealand. as covid vaccin
RGC Ratings Summary
RGC Quant Ranking